Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
RedHill Biopharma ( (RDHL) ) has provided an announcement.
On January 21, 2025, RedHill Biopharma announced that Talicia is now covered by Humana’s Part D Plan, expanding access to more than eight million additional Medicare lives without requiring prior authorization. The product is recognized as a first-line treatment for H. pylori infection by the American College of Gastroenterology, and a recent label change approved by the FDA allows for a simplified dosing schedule that supports better patient adherence. This development could enhance RedHill’s market positioning and its product’s reach in the U.S. healthcare landscape.
More about RedHill Biopharma
RedHill Biopharma is a specialty biopharmaceutical company focused on the development and commercialization of clinical-stage drugs for gastrointestinal diseases. Its primary product, Talicia, is an FDA-approved therapy for the treatment of H. pylori infection, a significant risk factor for gastric cancer and peptic ulcer disease.
YTD Price Performance: -11.94%
Average Trading Volume: 16,249
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $7.18M
For detailed information about RDHL stock, go to TipRanks’ Stock Analysis page.
